SM
NTLA icon

Sabby Management’s Intellia Therapeutics NTLA Stock Holding History

Sabby Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-452
Closed -$723K – 194
2017
Q2 		$723K Buy
452
+200
+79% +$2.79K 0.05% 118
2017
Q1 		$355K Buy
+252
New +$3.38K 0.02% 194

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Sabby Management's NTLA Position: Q4 2017 in Review

Sabby Management sold out of Intellia Therapeutics (NTLA) in Q4 2017, closing a stake of 11,281 shares — an estimated $280K sold.

Sabby Management first reported a position in NTLA in Q3 2016 and held it in 5 quarters. The position peaked at $1.97M in Q1 2017. 112 funds tracked by Wall St. Rank hold NTLA as of Q4 2017.

  • Sabby Management reported no remaining Intellia Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Sabby Management sold 11,281 Intellia Therapeutics shares in Q4 2017, an estimated $280K.
  • Sabby Management first reported a position in Intellia Therapeutics in Q3 2016 and held it in 5 quarters.
  • Sabby Management's Intellia Therapeutics position peaked at $1.97M in Q1 2017.
  • 112 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2017.

Based on Sabby Management's 13F filing for Q4 2017, filed 14 Feb 2018.